MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s11523-019-00691-z

Медицинская библиотека · Targeted oncology · 2020

Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study.

Kim Seung Tae, Hong Jung Yong, Lee Jeeyun, Park Joon Oh, Lim Ho Young, Kang Won Ki, Park Young Suk

Клиническое исследование II фазыСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Despite new agents to treat metastatic colorectal cancer (CRC), patients eventually progress and additional therapies are needed.

OBJECTIVE

We intended to evaluate the combination of pemetrexed/erlotinib in patients with high epidermal growth factor receptor (EGFR)-expressing (2+ or 3 on immunohistochemistry) metastatic CRC who experienced disease progression after standard chemotherapy.

PATIENTS AND

METHODS

We investigated pemetrexed and erlotinib (pemetrexed 500 mg/m2 on Day 1 and erlotinib 100 mg/m2 on Days 1-21) as a salvage treatment, given every 3 weeks, until disease progression or intolerable toxicity. The primary outcome was overall response rate (RR).

RESULTS

From May 2017 to April 2018, 29 metastatic CRC patients with high EGFR expression who had previously received standard therapies were enrolled into this trial. The regimen was well tolerated. Skin rash, vomiting, fatigue, and anorexia were common toxic effects but were mostly manageable and controllable side effects of grades 1 or 2 only. In an intent-to-treat analysis, three partial responses (PRs) were observed in enrolled patients, revealing an overall RR of 10.3%. This value supported the statistical hypothesis of this study. Fifteen patients had stable disease and the disease control rate (DCR) was 62.1%. All three patients who achieved a PR had a tumor EGFR expression of 3+. Among the eight patients with EGFR 3+ expression, the RR and DCR were 37.5% and 75.0%, respectively.

CONCLUSION

This phase II trial using pemetrexed/erlotinib in metastatic CRC with high EGFR expression met the primary endpoint of tumor response.

TRIAL REGISTRATION: This study was registered at ClinicalTrials.gov (number NCT03086538).

Для цитирования: Kim Seung Tae, Hong Jung Yong, Lee Jeeyun, Park Joon Oh, Lim Ho Young, Kang Won Ki, Park Young Suk. Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study.. Targeted oncology. 2020. DOI: 10.1007/s11523-019-00691-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.